Full text is available at the source.
Abstract
Intramuscular injection of the targeted mRNA vaccine STLNPs-Man results in a four-fold higher uptake by dendritic cells compared to commercially used lipid nanoparticles.
- Targeting dendritic cells using mannose receptor-mediated endocytosis enhances mRNA delivery.
- The STLNPs-Man@mRNA vaccine shows comparable antitumor efficacy with one-fifth the dosage of traditional mRNA vaccines.
- Reduced side effects are associated with the lower dosage of the STLNPs-Man@mRNA vaccine.
- The STLNPs-Man@mRNA vaccine downregulates a protein associated with T cell inhibition, potentially improving antitumor responses.
Simplified